Académique Documents
Professionnel Documents
Culture Documents
Dr. Lukman Hakim Zain Divisi Gastroenterologi Bag IPD FKUSU/RS HAM Medan.
Parasitic
Viral
Noninfectious
Hepatitis E virus
Hepatitis D virus Hepatitis G virus
Enterically transmitted
Coinfection with HBV Parenterally transmitted
A
NANB
Enterically E transmitted
B D
F, G, ? other
Parenterally C transmitted
A
Source of virus Route of transmission Chronic infection feces
E
feces
blood/ blood/ blood/ blood-derived blood-derived blood-derived body fluids body fluids body fluids
fecal-oral percutaneous percutaneous percutaneous fecal-oral permucosal permucosal permucosal no yes yes yes no
Prevention
pre/postpre/post- blood donor pre/post- ensure safe exposure exposure screening; exposure drinking immunization immunization risk behavior immunization; water modification risk behavior modification
MEASUREMENT
Conjugated bilirubin Conjugated and unconjugated bilirubin Hepatocellular damage Hepatocellular damage Intrahepatic or extrahepatic obstruction Clotting mechanism
HEPATITIS A VIRUS
RNA Picornavirus
Single serotype worldwide Acute disease and asymptomatic infection
No chronic infection
Protective antibodies develop in response to infection - confers lifelong immunity
age group:
Rare complications:
Fulminant hepatitis Cholestatic hepatitis Relapsing hepatitis Average 30 days Range 15-50 days None
Infection
Response
Viremia
HAV in stool
10
11
12
13
Week
Body Fluids
Serum Saliva
Urine
100
102
104
106
108
1010
Low
Very low
PREVENTING HEPATITIS A Hygiene (e.g., hand washing) Sanitation (e.g., clean water sources) Hepatitis A vaccine (pre-exposure) Immune globulin (pre- and post-exposure)
HEPATITIS A VACCINES
Highly immunogenic 97%-100% of children, adolescents, and adults
have protective levels of antibody within 1 month of receiving first dose; essentially 100% have protective levels after second dose
Highly efficacious In published studies, 94%-100% of children
38,157
94% (79%-99%)
1,037
100% (85%-100%)
At least 5-8 years among adults and children No cases in vaccinated children at 5-6 years of follow-up
Efficacy
Mathematical models of antibody decline suggest protective antibody levels persist for at least 20 years Other mechanisms, such as cellular memory, may contribute
Hepatitis B Virus
HBV
HBV nomenclature
HBV: hepatitis B virus HBsAg: hepatitis B virus surface antigen HBcAg: hepatitis B virus core antigen
HBV Epidemiology
Horizontal transmission
Person-to-person spread
Parenteral Sexual
Vertical transmission
Chronically infected mother to child
At birth or via breast milk
HBV Pathology
Portal of entry
Percutaneous is most efficient Sexual or perinatal is less efficient but major source
HBV Epidemiology
Icteric phase: liver damage: jaundice, dark urine, pale stools Recovery: decline in fever; renewed appetite
HBV Diagnosis
Clinical
Symptoms Looks like HAV
HBV Diagnosis
Laboratory
Liver enzymes Serology
HBeAg, HBcAg, virus: active infection Anti-HBc IgM: acute active infection Anti-HBe IgG: acute infection
HBV Treatment
Supportive Interferon-: many side effects Other antiviral drugs
Lamivudine: during viral infection Famciclovir: reverse transcriptase inhibitor
HBV Complications
Fulminate hepatitis Chronic hepatitis
5%-10% of HBV infections 10% of these progress to cirrhosis/liver failure At higher risk for fulminant hepatitis
HBV Complications
Chronic HBsAg antigenemia Chronic persistent hepatitis (CPH)
HBV Prevention
Screen blood products Sterilization of needles, etc. Avoiding intimate contact, e.g., household or sexual contacts Vaccination
Subunit vaccines HBsAg